- Home
- DSS vs SNGX Comparison
DSS vs SNGX Comparison
Compare DSS & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- SNGX
- Stock Information
- Founded
- DSS 1984
- SNGX 1987
- Country
- DSS United States
- SNGX United States
- Employees
- DSS N/A
- SNGX N/A
- Industry
- DSS Containers/Packaging
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DSS Consumer Discretionary
- SNGX Health Care
- Exchange
- DSS Nasdaq
- SNGX Nasdaq
- Market Cap
- DSS 7.3M
- SNGX 6.1M
- IPO Year
- DSS N/A
- SNGX 1987
- Fundamental
- Price
- DSS $0.87
- SNGX $2.21
- Analyst Decision
- DSS
- SNGX
- Analyst Count
- DSS 0
- SNGX 0
- Target Price
- DSS N/A
- SNGX N/A
- AVG Volume (30 Days)
- DSS 82.9K
- SNGX 31.7K
- Earning Date
- DSS 03-31-2025
- SNGX 03-21-2025
- Dividend Yield
- DSS N/A
- SNGX N/A
- EPS Growth
- DSS N/A
- SNGX N/A
- EPS
- DSS N/A
- SNGX N/A
- Revenue
- DSS $19,097,000.00
- SNGX $119,371.00
- Revenue This Year
- DSS N/A
- SNGX N/A
- Revenue Next Year
- DSS N/A
- SNGX $119.78
- P/E Ratio
- DSS N/A
- SNGX N/A
- Revenue Growth
- DSS N/A
- SNGX N/A
- 52 Week Low
- DSS $0.77
- SNGX $1.83
- 52 Week High
- DSS $2.30
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- DSS 43.96
- SNGX 46.98
- Support Level
- DSS $0.78
- SNGX $2.25
- Resistance Level
- DSS $1.03
- SNGX $2.41
- Average True Range (ATR)
- DSS 0.10
- SNGX 0.11
- MACD
- DSS -0.00
- SNGX -0.01
- Stochastic Oscillator
- DSS 25.97
- SNGX 56.45
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).